August 2025 in “Dermatology and Therapy” This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.
July 2026 in “Nature Communications” This study used spatial transcriptomics to investigate T cell-hair follicle interactions in cutaneous lupus erythematosus across mice, dogs, and humans, finding that CXCR3+ T cells and B cells are enriched in lesional skin, with implications for potential therapeutic targets.
This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.
This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.
April 2023 in “Journal of Investigative Dermatology” This study found that isotretinoin decreases mTORC1 signaling in acne skin, suggesting that mTOR inhibitors may have potential therapeutic benefits for acne patients.